{'fraction_non_alphanumeric': 0.04445611271549838, 'fraction_numerical': 0.02879145882558852, 'mean_word_length': 4.902892561983471, 'pattern_counts': {'":': 0, '<': 6, '<?xml version=': 0, '>': 4, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
XPO1 inhibitors represent a novel therapeutic option in Adult T-cell Leukemia, triggering p53-mediated caspase-dependent apoptosis

Dear Editor, Human T-cell Leukemia Virus type 1 (HTLV-1) is the etiological agent of adult T-cell leukemia (ATL). Although the majority of HTLV-1-infected individuals remain asymptomatic, in endemic regions such as Southern Japan, the Caribbean, some parts of Oceania, Romania, Central and South America, Northern Iran, and Central Africa, up to 4% of people living with HTLV-1 develop ATL. Although combination therapy with IFN-α and AZT as a first-line treatment prolongs survival of patients with ATL significantly, prognosis for patients with aggressive forms of ATL is poor due to intrinsic chemoresistance and relapse. The viral proteins Tax and HBZ play a major role in HTLV-1-induced carcinogenesis. Tax drives the ATL epigenetic signature through the NF-κB pathway and inactivates the tumor-suppressor protein p53. Inhibition of exportin-1 (CRM1/XPO1), the key nuclear export factor for proteins containing the typical leucine-rich nuclear export signal (NES), has been shown to inhibit NF-κB activity and induce p53-signaling pathways, whereas XPO1 inhibitors display efficacy against different types of cancer. Recently, the first-in-class XPO1 inhibitor selinexor (XPOVIO) has been approved by the US Food and Drug Administration for the treatment of relapsed and refractory multiple myeloma and for relapsed diffuse large B-cell lymphoma. Selinexor is a highly selective and covalent inhibitor of XPO1 preventing export of cargo proteins to the cytoplasm, resulting in nuclear accumulation of cargo proteins. Here, we investigate the therapeutic potential of selinexor in ATL by combining a two-stage targeted and systems analysis of ex vivo ATL transcriptomes with functional validation HTLV-1-transformed CD4+ cells. Since ATL leukemic cells are characterized as CD4CD25CADM1, we first investigated the possible relationship of XPO1 to these three signature genes, as well to p53 and NFκB signaling, which are the major regulators of apoptosis and survival in ATL. As shown in Fig. 1A, ATL patients display an XPO1 phenotype as compared to healthy controls, which was significantly and positively correlated to ATL leukemic markers CD4, CD25/IL2RA and CADM1/TSCL1 in two independent patient cohorts from different HTLV-1 endemic areas (Brazilian cohort, n= 9; Fig. 1C and Supplementary Fig. 1 for Japanese cohort, n= 44). In contrast, a strong negative correlation between XPO1 and IL2RA was observed in PBMCs from healthy controls in the Brazilian cohort (Fig. 1A), which we validated in purified CD4+ cells from a large independent cohort of healthy controls (Supplementary Fig. 1, r=−0.23, p < 0.0001, n= 294). This suggests a pathobiological role for XPO1 in ATL leukemogenesis. Likewise, increased XPO1 transcript levels were found to be associated with clinical progression to aggressive ATL (Fig. 1B). Noteworthy, XPO1 expression neither differed between Hbz-high expressing (>10 transcripts per million, TPM) or Hbzlow expressing (<10 TPM) ATL patients, nor was there

The viral proteins Tax and HBZ play a major role in HTLV-1-induced carcinogenesis 2 . Tax drives the ATL epigenetic signature through the NF-κB pathway and inactivates the tumor-suppressor protein p53 [3][4][5] . Inhibition of exportin-1 (CRM1/XPO1), the key nuclear export factor for proteins containing the typical leucine-rich nuclear export signal (NES), has been shown to inhibit NF-κB activity and induce p53-signaling pathways 6 , whereas XPO1 inhibitors display efficacy against different types of cancer [7][8][9] . Recently, the first-in-class XPO1 inhibitor selinexor (XPOVIO ® ) has been approved by the US Food and Drug Administration for the treatment of relapsed and refractory multiple myeloma and for relapsed diffuse large B-cell lymphoma. Selinexor is a highly selective and covalent inhibitor of XPO1 preventing export of cargo proteins to the cytoplasm, resulting in nuclear accumulation of cargo proteins [10][11][12] . Here, we investigate the therapeutic potential of selinexor in ATL by combining a two-stage targeted and systems analysis of ex vivo ATL transcriptomes with functional validation HTLV-1-transformed CD4+ cells.
Since ATL leukemic cells are characterized as CD4 + CD25 + CADM1 + , we first investigated the possible relationship of XPO1 to these three signature genes, as well to p53 and NFκB signaling, which are the major regulators of apoptosis and survival in ATL [13][14][15] . As shown in Fig. 1A, ATL patients display an XPO1 hi phenotype as compared to healthy controls, which was significantly and positively correlated to ATL leukemic markers CD4, CD25/IL2RA and CADM1/TSCL1 in two independent patient cohorts from different HTLV-1 endemic areas (Brazilian cohort 13-15 , n = 9; Fig. 1C and Supplementary Fig. 1 for Japanese cohort [13][14][15] , n = 44). In contrast, a strong negative correlation between XPO1 and IL2RA was observed in PBMCs from healthy controls in the Brazilian cohort (Fig. 1A), which we validated in purified CD4+ cells from a large independent cohort of healthy controls ( Supplementary Fig. 1, r = −0.23, p < 0.0001, n = 294). This suggests a pathobiological role for XPO1 in ATL leukemogenesis. Likewise, increased XPO1 transcript levels were found to be associated with clinical progression to aggressive ATL (Fig. 1B). Noteworthy, XPO1 expression neither differed between Hbz-high expressing (>10 transcripts per million, TPM) or Hbzlow expressing (<10 TPM) ATL patients, nor was there any difference in XPO1 expression between Tax-positive and Tax-negative ATL patient samples (p > 0.7 for both, Fig. 1B, inset). Furthermore, the combined XPO1 hi IL2RA hi phenotype was unique to ATL transcriptomes, as it was absent in other acute lymphocytic leukemias (B-ALL and T-ALL, Supplementary Fig. 1). Therefore, we proceeded to a genome-wide systems analysis of XPO1 in ATL, using a modular approach to integrate molecular, cellular and clinical data from both ATL cohorts. Whole Genome Correlation Network Analysis (WGCNA) of transcriptome data identified 31 unique gene modules in two independent ATL cohorts and confirmed XPO1 belongs to the same transcriptional module as leukemic marker CADM1 (Fig. 1C). Moreover, WGCNA also confirmed CD4 as a significant member of the XPO1 gene module in both cohorts (p = 0.018 and p = 1.45 ×10 −5 , data not shown). In agreement with this finding, we observed a significant positive correlation between XPO1 and CD4 transcript levels (a proxy for total CD4 + leukemic cells) and a negative correlation for CD8B transcripts (a proxy for antileukemic CD8 + cells) in the Japanese cohort, which we confirmed by flow cytometry in the Brazilian cohort (Fig.  1C). Hinting at a possible link to apoptosis, the XPO1 gene module comprised TP53 (the gene encoding apoptosis regulator p53) and several proapoptotic caspases ("executors" CASP3 and CASP7, "initiator" CASP10, all p < 0.05). As a negative control, we found that inflammatory caspases CASP1, CASP4, and CASP5 were not correlated to the XPO1 gene module (p > 0.30 in both cohorts, not shown). XPO1 transcript levels were also not correlated to gender (not shown), age, or patient survival ( Fig. 1C), arguing against a possible selection bias in ATL patients that might drive the observed XPO1 results. However, we found a a significant positive correlation of CASP3 (r = 0.741, p = 0.03) and CASP7 (r = 0.84, p < 0.01) with age at ATL diagnosis, suggesting that apoptosis might be protective in vivo by leading to later disease onset. In addition, "executor" caspase CASP7 (r = 0.82, p = 0.01) was positively correlated to ex vivo apoptosis, measured by short-term culture of unstimulated patient PBMCs. In agreement with a protective role for apoptosis in ATL, CASP10 levels showed a trend of correlation to longer survival (r = 0.64, p = 0.08), which remains to be investigated in larger cohorts. Unfortunately, no functional assay or survival data were available for the larger Japanese cohort.
XPO1 expression is strongly correlated to NFKB1 and TP53 transcript levels ( Fig. 1A-C), which are master regulators of cell survival and cell death in ATL, respectively, as has been extensively demonstrated both in vitro and in vivo [13][14][15] . Since obtaining fresh ATL leukemic cells of sufficient quality and quantity is a limiting factor for mechanistic in vitro studies, we used HTLV-1transformed CD4 + T-cell lines (MT-2 and MT-4) to elucidate the effect of XPO1 inhibition by selinexor (KPT-330, XPOVIO ® ) upon p53 signaling and downstream apoptosis. As shown in Fig. 2A, selinexor strongly induced p53 upregulation as well as phosphorylation, in a dosedependent manner, in both MT-2 and MT-4 cell lines. Selinexor treatment also caused nuclear accumulation of both p53 and IκB, as both proteins are indeed known cargo of XPO1 (Supplementary Fig. 2A). Nuclear p53 accumulation ( Supplementary Fig. 2B) was accompanied with a functional p53 response as evidenced by upregulation of its downstream effector Bax (Supplementary Fig.  2C). In parallel with p53 activation, selinexor treatment of MT-2 and MT-4 cell lines resulted in increased cell death (Fig. 2B), mediated by apoptosis, as suggested by annex-inV/PI staining (Fig. 2C). We confirmed the apoptotic nature of selinexor-induced cell death by western blot analysis of PARP cleavage and caspase-3 activation ( Supplementary Fig. 2D). Following up on the ex vivo results obtained for CASP3, CASP7, and CASP10 in ATL patients, we found that a pan-caspase inhibitor Q-VD-OPh (targeting caspases 3-7-8-9-10-12) was able to completely block PARP cleavage and caspase-3 activation ( Supplementary Fig. 2D), as well as apoptotic cell death (not shown). Selinexor treatment also caused a significant decrease in XPO1 protein levels ( Supplementary Fig. 2E).
We and others have previously demonstrated that a combined in vitro, ex vivo and in silico approach might recapitulate the ATL in vivo response [16][17][18][19] . In addition, we have also shown that HTLV-1-transformed MT-2 and MT-4 cells phenocopy primary ATL cells 18 in their relative resistance to the antiproliferative and proapoptotic effects of IFN-α 16,17 . Analogous to our findings with selinexor, we previously demonstrated that the significant antiproliferative and proapoptotic effect of IFN-β, but not IFN-α, was linked to increased p53 signaling in primary ATL cells 16 .
Of note, the XPO1 gene module we identified in ATL patients also contained IRF4 (data not shown), which has been identified as a sensitive predictor of IFN + AZT therapy failure 20 . Therefore, IRF4-overexpressing patients 21 likely to fail first-line therapy might preferentially benefit from XPO1 targeting.
In conclusion, this study demonstrates that pharmacological inhibition of XPO1 by selinexor is a potential novel therapeutic strategy in ATL, by triggering the proapoptotic p53 pathway leading to caspase-dependent apoptosis. With selinexor (XPOVIO ® ) currently already available for the treatment of multiple myeloma and DLBCL and under investigation in multiple clinical trials for hematological and solid malignancies, these data provide a strong rationale for further therapeutic   Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.